Safety, pharmacokinetics, pharmacogenomics and <scp>QT</scp> concentration−effect modelling of the <scp>SirT1</scp> inhibitor selisistat in healthy volunteers

Abstract

Selisistat was safe and well tolerated by healthy male and female subjects after single doses up to 600 mg and multiple doses up to 300 mg day(-1).